Inventaire - your friends and communities are your best library - Inventaire

Emerging drugs and combinations to treat multiple myeloma

author

Francesca Gay

published in: Oncotarget

date of publication: 2017-07-15

language: English

Cites articles 93

Date

Title

Authors

2017-02-01

m-TOR inhibitors and their potential role in haematological malignancies

Teresa Calimeri
2017-03-17

Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup.

Athanasios Dimopoulos, Albert Oriol, Gianluca Gaidano, Thierry Facon, Ruben Niesvizky, Hartmut Goldschmidt, Antonio Palumbo, Philippe Moreau, Heinz Ludwig, Katja Weisel, Alexander Suvorov, Sanjay Aggarwal, Wee Joo Chng, Ludek Pour, Roman Hajek, Tomas Pika, Vesselina Goranova-Marinova, Heidi H Gillenwater, Nehal Mohamed
2016-12-22

Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial

Bart Barlogie, Antje Hoering, Angela Dispenzieri, S. Vincent Rajkumar, Robert Z Orlowski, Muneer H Abidi, Stephen P Kahanic, Frederic J Reu, Rachael Sexton, Brian Durie
2016-10-01

Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma

Hareth Nahi, Albert Oriol, Athanasios Dimopoulos, Philippe Moreau, Paul G. Richardson, Hartmut Goldschmidt, Robert Z Orlowski, Mieczyslaw Komarnicki, Jesús San Miguel, Nizar J Bahlis, Saad Z Usmani, Donna E Reece, Torben Plesner, Tahamtan Ahmadi, Nushmia Z Khokhar, Kenshi Suzuki, Steen Lisby
2016-08-01

Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma

Ivan Špička, Tamas Masszi, Pieter Sonneveld, Antonio Palumbo, Katja Weisel, Meral Beksac
2016-07-19

Elotuzumab in combination with thalidomide and low-dose dexamethasone: a phase 2 single-arm safety study in patients with relapsed/refractory multiple myeloma

Albert Oriol, Joaquin Martinez-Lopez, Mercedes Gironella, Jesús San Miguel, María Victoria Mateos, Joan Bladé
2016-06-06

Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study

Adam D Cohen, Gordon J. Freeman, Margaret A Shipp
2016-01-01

New Targets and New Agents in High-Risk Multiple Myeloma

Sagar Lonial
2016

Clinical use and applications of histone deacetylase inhibitors in multiple myeloma

Shaji K Kumar
2016-05-23

Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma

Sagar Lonial, Paul G. Richardson, Henk M. Lokhorst
2016-05-12

CHAMPION-1: a phase 1/2 study of once-weekly carfilzomib and dexamethasone for relapsed or refractory multiple myeloma
2016-04-01

Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

Irwindeep Sandhu, Peter Ganly, Norbert Grzasko, Antonio Palumbo, Paul G. Richardson, Philippe Moreau, Francis K Buadi, Shaji K Kumar, Cyrille Touzeau
2016-04-18

Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM.

Andrzej Jakubowiak, Massimo Offidani, Javier de la Rubia, Alberto Bosi, Roberto Marasca, Antonio Palumbo
2016-03-21

Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group

Hervé Avet-Loiseau, Robert A Kyle, Sagar Lonial, Kenneth C. Anderson, Pieter Sonneveld, Hermann Einsele, Hartmut Goldschmidt, Antonio Palumbo, Philippe Moreau, Robert Z Orlowski, Niels W C J van de Donk
2016-03-01

Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma

Hui-Yi Lin
2016-09-19

Vemurafenib in combination with cobimetinib in relapsed and refractory extramedullary multiple myeloma harboring the BRAF V600E mutation.
2016-01-06

Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial.

Albert Oriol, Javier de la Rubia, Sagar Lonial, Paul G. Richardson, Robert Z Orlowski, Brendan M Weiss, Saad Z Usmani, Nizar J Bahlis, Amrita Y Krishnan, Joan Bladé, María Victoria Mateos, Steen Lisby, Seema Singhal, Ajai Chari, Natalie Callander
2015-11-16

Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b-2 dose-escalation study

Sagar Lonial, Kenneth C. Anderson, Philippe Moreau, Paul G. Richardson, Thierry Facon, Donna E Reece, Sundar Jagannath, Ravi Vij, Lotfi Benboubker, Jeffrey A Zonder, Eric Bleickardt, Sagar Lonial, Marc S Raab, Andrzej Jakubowiak
2015-12-03

Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study

Massimo Offidani, Albert Oriol, Athanasios Dimopoulos, Gianluca Gaidano, Philippe Moreau, Hartmut Goldschmidt, Antonio Palumbo, Thierry Facon, Heinz Ludwig, Robert Z Orlowski, Katja Weisel, Gianluca Gaidano, Alexander Suvorov, Wee Joo Chng, Ludek Pour, Roman Hajek, Tomas Pika, Vesselina Goranova-Marinova, Leonard Minuk, Vania Hungria, Heidi H Gillenwater, Nehal Mohamed, Ievgenii I Karamanesht
2015-12-02

Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment

Monika Sopala, Ashraf Elghandour, Athanasios Dimopoulos, Sagar Lonial, Hermann Einsele, Philippe Moreau, Paul G. Richardson, Wiesław Jędrzejczak, Vania Hungria, Thanyaphong Na Nakorn, Noppadol Siritanaratkul, Robert Schlossman, Claudia Corrado, Bourras-Rezki Bengoudifa, Florence Binlich, Andreas Günther, Jesús San Miguel, Meral Beksac
2015-09-17

Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma

Adam D Cohen, David D. Smith, Robert Z Orlowski, Cristina Gasparetto, Edward A. Stadtmauer, Jatin J Shah, Brian Durie
2015-09-24

Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma

Hareth Nahi, Ulrik Lassen, Jakub Krejcik, Antonio Palumbo, Paul G. Richardson, Monique C Minnema, Niels W C J van de Donk, Henk M. Lokhorst
2015-08-14

Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomib

Angela Dispenzieri, S. Vincent Rajkumar, Morie A Gertz, Martha Q Lacy, Francis K Buadi, A A Chanan-Khan
2015-06-02

Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma

Ivan Špička, Athanasios Dimopoulos, Sagar Lonial, Kenneth C. Anderson, Hermann Einsele, Antonio Palumbo, Paul G. Richardson, Philippe Moreau, Robert Z Orlowski, Sebastian Grosicki, Christoph Röllig, Adam Walter-Croneck, Donna E Reece, Jesús San Miguel, María Victoria Mateos, Andrew Belch, Eric Bleickardt, Valerie Poulart, Meral Beksac
2015-05-15

Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma

Hervé Avet-Loiseau, Florence Magrangeas, Kenneth C. Anderson, Paul G. Richardson, Nikhil V Munshi, Mehmet K Samur, Stéphane Minvielle, Jacob P Laubach, Hiroto Ohguchi, Noopur Raje, Teru Hideshima, Giada Bianchi, Gullu T Gorgun, Rikio Suzuki, Shohei Kikuchi
2015-04-28

Anti-programmed cell death protein-1/ligand-1 therapy in different cancers
2015-04-01

Immune checkpoint blockade in hematologic malignancies
2015-02-14

Activity of everolimus (RAD001) in relapsed and/or refractory multiple myeloma: a phase I study

Christian Kellner
2015-02-06

Phase 1 study in Japan of siltuximab, an anti-IL-6 monoclonal antibody, in relapsed/refractory multiple myeloma
2015-01-01

A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma

Liana Gercheva, Tamas Masszi, Tamás Masszi, Athanasios Dimopoulos, Ivan Špička, Robert Z Orlowski, Tadeusz Robak
2015-01-08

Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma

Vladimir Maisnar, Albert Oriol, Athanasios Dimopoulos, Philippe Moreau, Ruben Niesvizky, S. Vincent Rajkumar, Antonio Palumbo, Heinz Ludwig, Jesús San Miguel, Alexander Suvorov, Naseem Zojwalla, Margaret E. Tonda, Roman Hajek, Vesselina Goranova-Marinova, María Victoria Mateos, Jiri Minarik, Vishal Kukreti
2014-11-14

Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study

Parameswaran Hari, Sagar Lonial, Ruben Niesvizky, Paul G. Richardson, Shaji K Kumar

Article - wd:Q41694198

Welcome to Inventaire

the library of your friends and communities

you are offline